Hanmi's poziotinib faces uncertainty due to unfavorable feedback from FDA scientists
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
In a briefing document for its scientist session on Wednesday, the FDA said poziotinib may not provide a meaningful advantage over available therapies and additional analyses will be required.
Poziotinib is an oral tyrosine kinase inhibitor to treat patients with previously treated locally advanced or metastatic NSCLC harboring the human epidermal growth factor receptor exon 20 insertion mutation. The drug was licensed out to U.S. Spectrum which is seeking an FDA approval.
The FDA scientists said the data provided shows a low 28 percent overall response rate (ORR) and the safety profile is poor as 85 percent of patients had grade 3-4 adverse events.
Spectrum and Hanmi immediately refuted the statement, saying it should be noted that this drug provides a new option for patients for whom there is no cure today.
The adverse events of poziotinib are predictable and manageable, and the benefits clearly outweigh the risks, said a Hanmi official, stressing the drug’s usefulness as an orally taken second or third-line treatment for patients who do not respond to existing treatments.
Hanmi and Spectrum plan to highlight the drug’s clinical usefulness at the ODAC meeting to draw a positive recommendation. But the ODAC’s recommendation does not guarantee the FDA’s approval. The FDA’s final decision will come out by Nov. 24.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Yoon brings IRA attention during encounters with Biden in London and NY - Pulse by Maeil Business News Korea
- Lotte, Hanjin join Korea’s list of marginal firms incapable of affording debt interest - Pulse by Maeil Business News Korea
- BOK may study rate hike in 50bp Oct, to exchange currencies with NPS to ease USD - Pulse by Maeil Business News Korea
- USD-KRW above 1,400, 3-yr bond at 4% as Korean markets panic on tightening speed - Pulse by Maeil Business News Korea
- WKF: Liberal democracies lead to better quality in decision making: Fukuyama - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- AI가 실시간으로 가격도 바꾼다…아마존·우버 성공 뒤엔 ‘다이내믹 프라이싱’
- 서예지, 12월 29일 데뷔 11년 만에 첫 단독 팬미팅 개최 [공식] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이